Authors

Anthony Stein Gehr Family Center for Leukemia Research

Latest:

Dr. Tolcher on Utomilumab Plus Pembrolizumab in Advanced Solid Tumors

Anthony W. Tolcher, MD, director of clinical research at South Texas Accelerated Research Therapeutics San Antonio, discusses a phase Ib study examining the combination of the 4-1BB agonist utomilumab (PF-05082566) and pembrolizumab (Keytruda) as a treatment for patients with advanced solid tumors.

Antoinette Wozniak, MD, FACP, FASCO

Latest:

Dr. Wozniak on Optimizing the Use of Immunotherapy in NSCLC

Antoinette Wozniak, MD, FACP, FASCO, discusses optimizing the use of immunotherapy in patients with non–small cell lung cancer.

Antoni Ribas, MD

Latest:

Melanoma: Improving Clinical Outcomes Through Advances in Immunotherapeutics and Targeted Therapy

Metastatic melanoma has limited treatment options, but advances in the understanding of the oncogenic mutations that drive this cancer and how the immune system can be better modulated to fight melanoma provide a new generation of active approaches for patients.

Antoni Ribas, MD, PhD

Latest:

Dr. Ribas on Immune-Related Adverse Events in Melanoma

Antoni Ribas, MD, PhD, professor of medicine, University of California, Los Angeles, director, Tumor Immunology Program, Jonsson Comprehensive Cancer Center, discusses immune-related adverse events (irAEs) in melanoma.

Antoni Ribas, MD, PhD, University of California Los Angeles

Antonio C. Wolff, MD

Latest:

Dr. Wolff Discusses the Importance of HER2 Testing

Dr. Antonio C. Wolff from Sidney Kimmel Comprehensive Cancer Center Discusses the Importance of HER2 Testing

Antonio Gonzalez-Martin, MD

Latest:

Dr. González-Martín on Updated PFS Data From the PRIMA Trial in Advanced Ovarian Cancer

Antonio Gonzalez-Martin, MD, PhD, discusses new long-term progression-free survival data from the phase 3 PRIMA trial in advanced ovarian cancer.

Antonio Iavarone, MD

Latest:

Dr. Iavarone on the Role of the ID2 Protein in Brain Cancer

Antonio Iavarone, MD, professor of Pathology and Cell Biology and Neurology, Columbia University, Institute for Cancer Genetics, discusses the role of the ID2 protein in patients with malignant brain tumors.

Antonio Llombart-Cussac, MD, PhD

Latest:

Dr Llombart-Cussac on the Implications of Prophylaxis for Neutropenia and Diarrhea in Advanced Breast Cancer

Antonio Llombart-Cussac, MD, PhD, on the implications of prophylaxis for sacituzumab govitecan–related neutropenia and diarrhea in advanced breast cancer.

Antonio Palumbo, MD

Latest:

Dr. Palumbo on Significance of Daratumumab Triplet in Multiple Myeloma

Antonio Palumbo, MD, chief, Myeloma Unit, Department of Oncology, Section of Hematology, University of Torino, Italy, discusses the impact the triplet regimen of daratumumab (Darzalex), bortezomib (Velcade), and dexamethasone will have on the field of multiple myeloma.

Antonio Passaro, MD, PhD

Latest:

Dr Passaro on the Significance of the TROPION-Lung05 Trial of Dato-DXd in NSCLC

Antonio Passaro, MD, PhD, medical oncologist, Division of Thoracic Oncology, European Institute of Oncology, discusses the significance of data from the phase 2 TROPION-Lung05 trial of datopotamab deruxtecan in patients with non–small cell lung cancer.

Anuradha S. Budhu, PhD

Latest:

Potential Molecular Markers in Liver Cancer

Anuradha S. Budhu, PhD, discusses using molecular features as predictive markers in liver cancer.

Apar Kishor Ganti, MD

Latest:

Dr. Ganti on Lung Cancer Abstracts From the 2018 ASCO Annual Meeting

Apar Kishor Ganti, MD, professor of internal medicine, Division of Oncology/Hematology, University of Nebraska Medical Center, discusses lung cancer abstracts that were presented at the 2018 ASCO Annual Meeting.

Aparna R. Parikh, MD

Latest:

Dr Parikh on the Clinical Implications of Molecular Testing on mCRC Management

Aparna Parikh, MD, discusses the importance of upfront molecular testing in patients with metastatic colorectal cancer.

Apostolia M. Tsimberidou, MD, PhD

Latest:

Dr. Tsimberidou on the Impact Trial in Patients With Advanced Cancer

Apostolia Maria Tsimberidou, MD, PhD, tenured professor, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, discusses the IMPACT trial in patients with advanced cancer.

Apostolia Tsimberidou, MD, PhD

Latest:

Dr. Tsimberidou on the Next Steps for Personalized Care

Dr. Apostolia Tsimberidou from MD Anderson Cancer Center on the Next Steps for Personalized Care

Aradhana Kaushal, MD

Latest:

Primary Radiation Therapy for Myeloid Sarcoma of the Porta Hepatis

Treating myeloid sarcoma at the porta hepatis with 24 Gy over 12 fractions is a well-tolerated treatment that achieved a complete, durable response with minimal toxicity.

Arantxa Romero-Toledo, PhD

Latest:

Impact of BTK Inhibition on Monocytic Myeloid-Derived Suppressor Cells in CLL

Arantxa Romero-Toledo, PhD student, at the Centre for Haemato-Oncology, Barts Cancer Institute, discusses the impact of BTK inhibition on monocytic myeloid-derived suppressor cells (MDSCs) in chronic lymphocytic leukemia (CLL).

Areej R. El-Jawahri, MD

Latest:

Dr El-Jawahri on the Benefits of Earlier Palliative Care in Hematologic Malignancies

Areej El-Jawahri, MD, discusses the potential benefits of earlier palliative care for patients with hematologic malignancies.